The discovery of cancer progression mechanisms of immune evasion via upregulation of programmed cell death-1 (PD-1) ligand-1 (PD-L1) has led to targeted immunotherapies blocking the PD-1 axis [1]. This evidence concerns the gene PDCD1 and cancer.